<DOC>
	<DOCNO>NCT02881879</DOCNO>
	<brief_summary>The aim study evaluate safety tolerability subcutaneous immunotherapy ( SCIT ) House Dust Mite ( HDM ) extract patient rhinoconjunctivitis without associate mild asthma sensitize HDM . In addition , surrogate efficacy parameter evaluate : immunoglobulin level change skin reactivity . It recruit 50 patient susceptible receive SCIT HDM extract along 5 participate spanish site . Primary endpoint study assess safety tolerability subcutaneous immunotherapy depot presentation quick pattern patient rhinoconjunctivitis without mild asthma sensitize house dust mites Secondary objective evaluate indirect immunotherapy efficacy measurement immunoglobulin level change cutaneous reactivity</brief_summary>
	<brief_title>Clinical Trial With Subcutaneous Immunotherapy Depot Presentation Patients With Allergic Rhinoconjunctivitis Sensitized House Dust Mites</brief_title>
	<detailed_description>The aim present clinical trial go deep safety vaccine mixture DPT DF ( 50:50 ) . Although first clinical trial date perform vaccine , two clinical trial formulation DPT 100 % active ingredient ( NºEudraCT : 2009-016277-15 NºEudraCT : 2011-004583-30 ) . Given remarkable cross-reactivity DPT DF mite , result two clinical trial conduct date subcutaneous depot vaccine Dermatophagoides pteronyssinus 100 % extract mite , significant</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>1 . Patients must sign informed consent form 2 . Patients must 18 60 year age 3 . Patients perennial allergic rhinoconjunctivitis HDM minimum 1 year prior study participation . Although allergic rhinoconjunctivitis pathology study , inclusion patient mild concomitant asthma allow ( GINA 2015 ) 4 . Patients obtain prick test result ≥ 3 mm diameter HDM . Positive negative control test give consistent result 5 . Patients specific immunoglobulin E ≥ class 2 ( CAP/PHADIA ) HDM 6 . Patients sensitize HDM clinically relevant symptom treatment HDM ( 50:50 ) vaccine indicate 7 . Women childbearing potential must negative urine pregnancy test visit 1 8 . Women childbearing potential must agree use appropriate contraception method study sexually active 1 . Patients receive immunotherapy previous 5 year HDM allergen cross reactivity patient currently receive immunotherapy allergen 2 . Patients severe asthma forced expiratory volume 1 second FEV1 &lt; 70 % even pharmacologically control 3 . Polysensitized patient besides airborne allergen Dermatophagoides pteronyssinus Dermatophagoides farinae , accord investigator may present clinically relevant airborne allergen participate study 4 . Patients : immunological , cardiac , renal hepatic illness medical condition investigator deem relevant interfere study 5 . Patients previous history anaphylaxis 6 . Patients active chronic urticaria 7 . Patients active severe atopic eczema 8 . Patients participate another clinical trial within 3 month prior enrollment 9 . Patients treatment tricyclic antidepressives , phenothiazine , β blocker , Angiotensin Converting Enzyme Inhibitors ( ACEI ) 10 . Female patient pregnant breastfeed 11 . Patient attend visit 12 . Patient 's lack collaboration refusal participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>